Skip to main content
. 2012 Mar 1;2(3):393–405. doi: 10.1534/g3.111.001693

Table 1 . Summary of the screen for genetic modifiers of Zfrp8/+ lymph gland phenotype.

Deficiency Modifying Zfrp8/+ Lymph Gland Overgrowth Deleted Segment, Cytology Numbers of Lymph Glands with Phenotype/ Total Analyzed Comment on Mapping Modifying Alleles and RNAi Lines
Suppressing
 Df(2L)BSC31 23E5–23F5 7/13 Smaller deficiencies tested, no modifiers found. n/i
 Df(2L)BSC17 30C3–30F1 14/14 Mapped to 30C1 and 30C5. Two dominant suppressors identified. pelo1, hoipk07104
 Df(2R)cn9 42E–44C1 20/27 Not mapped. n/i
 Df(2R)BSC29 45D3–45F6 7/12 Mapped to 45F5–46A1. CG30338 {v 29189}
 Df(2R)en-A 47D3–48B2 6/11 Not mapped. n/i
 Df2R)BSC11 50E6–51E4 10/10 Mapped to 51A5—51C1. n/i
 Df(2R)PC4 55A1–55F2 9/10 Mapped to 55B11–55C9. nopo {v104477} Idgf5 {v100977}
 Df(2R)BSC22 56D7–56F12 10/19 Not mapped. n/i
 Df(2R)vir130 59B1–59E1 17/17 Smaller deficiencies tested, no modifiers found. n/i
 Df(2R)or-Br6 59D5–60B8 13/24 Weak modifier mapped to 59D9. CG30415EY04039
 Df(2R)M60E 60E6–60E11 20/21 Not mapped.
 Df(3L)BSC23 62E8–63B6 8/12 Not mapped.
 Df(3L)AC1 67A2–67D13 10/14 Two dominant suppressors identified. shcKG06847, vs.g EY05552, MTF-1 {v107124}
 Df(3L)Pc-2q 78C5–79A1 9/15 Not mapped. n/i
 Df(3R)mbc-30 95A5–95C11 9/10 Mapped to 95B1–95D1. n/i
Modifying Phenotype of trans-heterozygous lymph glands. Comment on mapping.
 Df(2L)net-PMF 21A1–21B8 9/12 Small CZ. Both enhancer and suppressor are found. l(2)gl4, smo3
 Df(2R)Egfr5 57D2–58D1 9/9 Small lymph gland with changed morphology. Not mapped. n/i
 Df(3L)emc-E12 61A–61D3 21/28 Lymph glands are enlarged and disintegrated. Enhancing region mapped to 61A5–61B1 and one suppressing gene mapped to 61B1. Pk61CEP3091, Pk61C5,
 Df(3L)W10 75A6–75C2 lethal Smaller deficiencies do not show lethality. Enhancing region is mapped to 74D1–75B11 Enhancer and suppressors found. Eip75BA81, Adgf-Ad11616, mus304D3, n/i
 Df(3L)BSC249 79B2–79D1 11/11 Disintegrated primary lobes. Not mapped. n/i
 Df(3R)ME15 81F3–82F7 14/14 Disintegrated primary lobes. Not mapped. n/i
Zfrp8-independent phenotypes Lymph gland phenotype of deficiency/+ Comment
  Df(2L)ast2 21D1–22B3 15/15 Lymph gland disintegration mapped to 21D4-21E2. Ush, lwr are known to cause hematopoietic phenotype
  Df(2L)c144 22F4–23C3 15/17 Increased size and differentiation.
  Df(2L)spdj2 27B2–27F2 10/10 Decreased size and small CZ.
  Df(2R)cn9 42E–44C1 27/27 Decreased size, increased differentiation.
  Df(2L)TW161 38A6–40B1 8/11 Decreased size, increased differentiation.
  Df(3L)XG5 71C2–72C1 19/19 Enlarged cortex.
  Df(3R)BSC38 85F1–86C8 6/10 Enlarged.
  Df(3R)T-32 86D9–87C4 13/17 Enlarged disintegrated.
  Df(3R)ea 88E7–89A1 18/18 Enlarged disintegrated.
  Df(3R)crb87-5 95F8–96A20 20/20 Primary lobe enlargement.

Columns 1 and 2 show the deficiencies that modify the Zfrp8null/+ phenotype in more than 50% of the lymph glands and their cytological location. Column 3 shows the number of lymph glands with modified phenotypes relative to the total number analyzed. Column 4 shows the smallest cytological interval to which the modifying effect was mapped. Column 5 lists the genes that were found to have modifying effect. n/i, modifying genes were not identified.